The Overlooked Risk of Venous Thromboembolism in Psychiatric Patients: Epidemiology, Pathophysiology, and Implications for Clinical Care

Abstract

Psychiatric patients face a significantly shorter life expectancy than the general population due to a complex interplay of medical, behavioral, and social factors. Venous thromboembolism (VTE), encompassing both pulmonary embolism and deep vein thrombosis, is an underrecognized yet critical contributor to morbidity and mortality in this population. Evidence suggests a two to three times higher prevalence of VTE in psychiatric patients compared to the general population, with incidence rates up to 4.5 per 1,000 person-years. This elevated risk is attributed to a hypercoagulable-hypofibrinolytic state. It is influenced by metabolic abnormalities, pro-inflammatory pathways, antipsychotic medications, and genetic factors. Health care biases and reduced treatment compliance further exacerbate the burden. This review explores the epidemiology, pathophysiology, and mechanistic underpinnings of VTE in psychiatric populations, emphasizing the role of metabolic syndrome and antipsychotic therapy. To mitigate mortality and enhance outcomes for these high-risk individuals, it is imperative to address this issue through improved risk stratification and preventive strategies.

Keywords

psychiatric diseases - venous thromboembolism - hypercoagulability - metabolic syndrome - antipsychotic drugs

Publication History

Article published online:
13 December 2024

• References

• 1 Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2007; 64 (05) 566-576
• 2 De Hert M. CS01–04 - Psychotic disorders and increased metabolic and cardiovascular morbidity in patients with schizophrenia. Recommendation for diagnoses and treatment. Eur Psychiatry 2012; 27 (S1): 1-1
• 3 DE Hert M, Correll CU, Bobes J. et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011; 10 (01) 52-77
• 4 Cook BL, Wayne GF, Kafali EN, Liu Z, Shu C, Flores M. Trends in smoking among adults with mental illness and association between mental health treatment and smoking cessation. JAMA 2014; 311 (02) 172-182
• 5 Chow V, Reddel C, Pennings G. et al. Global hypercoagulability in patients with schizophrenia receiving long-term antipsychotic therapy. Schizophr Res 2015; 162 (1–3): 175-182
• 6 Sapota-Zaręba K, Nasierowski T. The risk of pulmonary embolism in the context of various clinical situations and management in psychiatric patients. Psychiatr Pol 2023; 57 (05) 955-965
• 7 Corrigan PW, Druss BG, Perlick DA. The impact of mental illness stigma on seeking and participating in mental health care. Psychol Sci Public Interest 2014; 15 (02) 37-70
• 8 Booth WA, Abuhmida M, Anyanwu F. Mental health stigma: a conundrum for healthcare practitioners in conservative communities. Front Public Health 2024; 12: 1384521
• 9 Nauffal D, Ballester M, Reyes RL. et al; RIETE Investigators. Influence of recent immobilization and recent surgery on mortality in patients with pulmonary embolism. J Thromb Haemost 2012; 10 (09) 1752-1760
• 10 Kowal C, Peyre H, Amad A. et al. Psychotic, mood, and anxiety disorders and venous thromboembolism: a systematic review and meta-analysis. Psychosom Med 2020; 82 (09) 838-849
• 11 Velasco-Rodríguez D, Laso RV, García-Raso A. et al. Thrombin generation in subjects with lupus anticoagulant without prior thrombosis or gestational morbidities. Thromb Res 2020; 196: 425-431
• 12 Lin CE, Chung CH, Chen LF, Chien WC. Increased risk for venous thromboembolism among patients with concurrent depressive, bipolar, and schizophrenic disorders. Gen Hosp Psychiatry 2019; 61: 34-40
• 13 Rarrick C, Saccone N, Hebbard A, Jones B. Assessing the rate of antipsychotic use in ambulatory care patients with a venous thromboembolism. Ann Pharmacother 2020; 54 (02) 97-104
• 14 Ishida T, Katagiri T, Uchida H. et al. Incidence of deep vein thrombosis in restrained psychiatric patients. Psychosomatics 2014; 55 (01) 69-75
• 15 Delluc A, Tromeur C, Le Moigne E. et al. Lipid lowering drugs and the risk of recurrent venous thromboembolism. Thromb Res 2012; 130 (06) 859-863
• 16 Takeshima M, Ishikawa H, Umeta Y. et al. Prevalence of asymptomatic venous thromboembolism in depressive inpatients. Neuropsychiatr Dis Treat 2020; 16: 579-587
• 17 Ellis N, Grubb CM, Mustoe S. et al. Venous thromboembolism risk in psychiatric in-patients: a multicentre cross-sectional study. BJPsych Bull 2019; 43 (06) 255-259
• 18 Stefanović V, Kuzmanović A, Stefanović S. Fatal pulmonary thromboembolism after prolonged physical immobilization in hospitalized psychiatric patients. Vojnosanit Pregl 2013; 70 (10) 903-907
• 19 Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry 2015; 72 (04) 334-341
• 20 Gardner TA, Fuher A, Longino A. et al. Reduced mortality associated with pulmonary embolism response team consultation for intermediate and high-risk pulmonary embolism: a retrospective cohort study. Thromb J 2024; 22 (01) 38
• 21 Zghouzi M, Mwansa H, Shore S. et al. Sex, racial, and geographic disparities in pulmonary embolism-related mortality nationwide. Ann Am Thorac Soc 2023; 20 (11) 1571-1577
• 22 Björkenstam E, Ljung R, Burström B, Mittendorfer-Rutz E, Hallqvist J, Weitoft GR. Quality of medical care and excess mortality in psychiatric patients–a nationwide register-based study in Sweden. BMJ Open 2012; 2 (01) e000778
• 23 Kalman D, Morissette SB, George TP. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict 2005; 14 (02) 106-123
• 24 Tsuang MT, Woolson RF, Fleming JA. Premature deaths in schizophrenia and affective disorders. An analysis of survival curves and variables affecting the shortened survival. Arch Gen Psychiatry 1980; 37 (09) 979-983
• 25 Gregson J, Kaptoge S, Bolton T. et al; Emerging Risk Factors Collaboration. Cardiovascular risk factors associated with venous thromboembolism. JAMA Cardiol 2019; 4 (02) 163-173
• 26 Alberg A. The influence of cigarette smoking on circulating concentrations of antioxidant micronutrients. Toxicology 2002; 180 (02) 121-137
• 27 Wei Y, Lai B, Liu H, Li Y, Zhen W, Fu L. Effect of cigarette smoke extract and nicotine on the expression of thrombomodulin and endothelial protein C receptor in cultured human umbilical vein endothelial cells. Mol Med Rep 2018; 17 (01) 1724-1730
• 28 Fernández JA, Gruber A, Heeb MJ, Griffin JH, Protein C. Protein C pathway impairment in nonsymptomatic cigarette smokers. Blood Cells Mol Dis 2002; 29 (01) 73-82
• 29 Nedeljkovic ZS, Gokce N, Loscalzo J. Mechanisms of oxidative stress and vascular dysfunction. Postgrad Med J 2003; 79 (930) 195-199 , quiz 198–200
• 30 Yousefzadeh G, Sayyadi A, Najafipour H, Sabaghnejad V, Pezeshki S. Comparing the association of two metabolic syndrome definitions, NCEP ATP III and IDF, with the risk of developing atherosclerotic cardiovascular disease: an analytical cross-sectional study. Endocrinol Diabetes Metab 2024; 7 (01) e468
• 31 Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders–a systematic review and meta-analysis. Schizophr Bull 2013; 39 (02) 306-318
• 32 DE Hert M, Schreurs V, Vancampfort D, VAN Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009; 8 (01) 15-22
• 33 van Winkel R, Rutten BP, Peerbooms O, Peuskens J, van Os J, De Hert M. MTHFR and risk of metabolic syndrome in patients with schizophrenia. Schizophr Res 2010; 121 (1–3): 193-198
• 34 Aoki R, Saito T, Ninomiya K. et al. Shared genetic components between metabolic syndrome and schizophrenia: genetic correlation using multipopulation data sets. Psychiatry Clin Neurosci 2022; 76 (08) 361-366
• 35 Garrido-Torres N, Rocha-Gonzalez I, Alameda L. et al. Metabolic syndrome in antipsychotic-naïve patients with first-episode psychosis: a systematic review and meta-analysis. Psychol Med 2021; 51 (14) 2307-2320
• 36 Ward J, Le NQ, Suryakant S. et al. Polygenic risk of major depressive disorder as a risk factor for venous thromboembolism. Blood Adv 2023; 7 (18) 5341-5350
• 37 Darvall KAL, Sam RC, Silverman SH, Bradbury AW, Adam DJ. Obesity and thrombosis. Eur J Vasc Endovasc Surg 2007; 33 (02) 223-233
• 38 Engin A, Engin AB. (eds). Obesity and Lipotoxicity. Vol 1460. Cham: Springer International Publishing; 2024
• 39 Nieuwdorp M, Stroes ESG, Meijers JCM, Büller H. Hypercoagulability in the metabolic syndrome. Curr Opin Pharmacol 2005; 5 (02) 155-159
• 40 Dentali F, Squizzato A, Ageno W. The metabolic syndrome as a risk factor for venous and arterial thrombosis. Semin Thromb Hemost 2009; 35 (05) 451-457
• 41 Mertens I, Verrijken A, Michiels JJ, Van der Planken M, Ruige JB, Van Gaal LF. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond) 2006; 30 (08) 1308-1314
• 42 Davì G, Guagnano MT, Ciabattoni G. et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002; 288 (16) 2008-2014
• 43 Leucht S, Priller J, Davis JM. Antipsychotic drugs: a concise review of history, classification, indications, mechanism, efficacy, side effects, dosing, and clinical application. Am J Psychiatry 2024; 181 (10) 865-878
• 44 Holt RIG, Mitchell AJ. Diabetes mellitus and severe mental illness: mechanisms and clinical implications. Nat Rev Endocrinol 2015; 11 (02) 79-89
• 45 Lindekilde N, Scheuer SH, Rutters F. et al. Prevalence of type 2 diabetes in psychiatric disorders: an umbrella review with meta-analysis of 245 observational studies from 32 systematic reviews. Diabetologia 2022; 65 (03) 440-456
• 46 Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002; 162 (10) 1182-1189
• 47 Dicks AB, Moussallem E, Stanbro M, Walls J, Gandhi S, Gray BH. A comprehensive review of risk factors and thrombophilia evaluation in venous thromboembolism. J Clin Med 2024; 13 (02) 362
• 48 Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med 2007; 262 (02) 157-172
• 49 Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001; 15 (01) 44-54
• 50 Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993; 36 (11) 1119-1125
• 51 Boden G, Vaidyula VR, Homko C, Cheung P, Rao AK. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J Clin Endocrinol Metab 2007; 92 (11) 4352-4358
• 52 Meade TW, Mellows S, Brozovic M. et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2 (8506): 533-537
• 53 Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40 (04) 405-412
• 54 Li X, Zou J, Lin A. et al. Oxidative stress, endothelial dysfunction, and N-acetylcysteine in type 2 diabetes mellitus. Antioxid Redox Signal 2024; 40 (16–18): 968-989
• 55 Aso Y, Yoshida N, Okumura K. et al. Coagulation and inflammation in overt diabetic nephropathy: association with hyperhomocysteinemia. Clin Chim Acta 2004; 348 (1–2): 139-145
• 56 Chiva-Blanch G, Peña E, Cubedo J. et al. Molecular mapping of platelet hyperreactivity in diabetes: the stress proteins complex HSPA8/Hsp90/CSK2α and platelet aggregation in diabetic and normal platelets. Transl Res 2021; 235: 1-14
• 57 Lawrence D, Hancock KJ, Kisely S. The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ 2013; 346: f2539
• 58 Kim V, Goel N, Gangar J. et al; and the COPD Gene Investigators. Risk factors for venous thromboembolism in chronic obstructive pulmonary disease. Chronic Obstr Pulm Dis (Miami) 2014; 1 (02) 239-249
• 59 Ray JG, Mamdani MM, Yeo EL. Antipsychotic and antidepressant drug use in the elderly and the risk of venous thromboembolism. Thromb Haemost 2002; 88 (02) 205-209
• 60 Zheng C, Liu H, Tu W, Lin L, Xu H. Hypercoagulable state in patients with schizophrenia: different effects of acute and chronic antipsychotic medications. Ther Adv Psychopharmacol 2023; 13: 20 451253231200257
• 61 Lim GY, Tam WW, Lu Y, Ho CS, Zhang MW, Ho RC. Prevalence of depression in the community from 30 countries between 1994 and 2014. Sci Rep 2018; 8 (01) 2861
• 62 von Känel R, Merz F, Pfister H. et al. Evidence for an enhanced procoagulant state in remitted major depression. World J Biol Psychiatry 2020; 21 (10) 766-774
• 63 Morel-Kopp MC, McLean L, Chen Q. et al. The association of depression with platelet activation: evidence for a treatment effect. J Thromb Haemost 2009; 7 (04) 573-581
• 64 Geiser F, Gessler K, Conrad R, Imbierowicz K, Albus C, Harbrecht U. Can activation of coagulation and impairment of fibrinolysis in patients with anxiety and depression be reversed after improvement of psychiatric symptoms? Results of a pilot study. J Nerv Ment Dis 2012; 200 (08) 721-723
• 65 Song R, Shi Y, Li X. et al. Potential of antithrombin III as a biomarker of antidepressive effect in major depressive disorder. Front Psychiatry 2021; 12: 678384
• 66 Gris JC, Nobile B, Bouvier S. Neuropsychiatric presentations of antiphospholipid antibodies. Thromb Res 2015; 135 (Suppl. 01) S56-S59
• 67 Hoirisch-Clapauch S, Nardi AE. Psychiatric remission with warfarin: should psychosis be addressed as plasminogen activator imbalance?. Med Hypotheses 2013; 80 (02) 137-141
• 68 Hoirisch-Clapauch S, Amaral OB, Mezzasalma MAU, Panizzutti R, Nardi AE. Dysfunction in the coagulation system and schizophrenia. Transl Psychiatry 2016; 6 (01) e704-e704
• 69 Susai SR, Föcking M, Mongan D. et al. Association of complement and coagulation pathway proteins with treatment response in first-episode psychosis: a longitudinal analysis of the OPTiMiSE clinical trial. Schizophr Bull 2023; 49 (04) 893-902
• 70 Santa Cruz EC, Zandonadi FDS, Fontes W, Sussulini A. A pilot study indicating the dysregulation of the complement and coagulation cascades in treated schizophrenia and bipolar disorder patients. Biochim Biophys Acta Proteins Proteom 2021; 1869 (08) 140657
• 71 Vankwani S, Mirza MR, Awan FR. et al. Label free quantitative proteomic profiling of serum samples of intellectually disabled young patients revealed dysregulation of complement coagulation and cholesterol cascade systems. Metab Brain Dis 2024; 39 (05) 855-869
• 72 Kozłowska E, Agier J, Wysokiński A, Łucka A, Sobierajska K, Brzezińska-Błaszczyk E. The expression of toll-like receptors in peripheral blood mononuclear cells is altered in schizophrenia. Psychiatry Res 2019; 272: 540-550
• 73 Altamura AC, Buoli M, Pozzoli S. Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: comparison with schizophrenia. Psychiatry Clin Neurosci 2014; 68 (01) 21-36
• 74 Levi M, Schultz M, van der Poll T. Coagulation biomarkers in critically ill patients. Crit Care Clin 2011; 27 (02) 281-297
• 75 Momtazmanesh S, Zare-Shahabadi A, Rezaei N. Cytokine alterations in schizophrenia: an updated review. Front Psychiatry 2019; 10: 892
• 76 Bentur OS, Sarig G, Brenner B, Jacob G. Effects of acute stress on thrombosis. Semin Thromb Hemost 2018; 44 (07) 662-668
• 77 Ali-Saleh M, Sarig G, Ablin JN, Brenner B, Jacob G. Inhalation of a short-acting β2-adrenoreceptor agonist induces a hypercoagulable state in healthy subjects. PLoS One 2016; 11 (07) e0158652
• 78 Boushra M, Nagalli S. Neuroleptic Agent Toxicity [Updated July 3, 2023]. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2024
• 79 Masopust J, Malý R, Vališ M. Risk of venous thromboembolism during treatment with antipsychotic agents. Psychiatry Clin Neurosci 2012; 66 (07) 541-552
• 80 Waters K, Goodwin H, Morrow G. Clozapine-induced pulmonary embolism in a patient with minimal pre-existing risk factors. J Am Pharm Assoc (Wash DC) 2021; 61 (01) e53-e56
• 81 Jönsson AK, Schill J, Olsson H, Spigset O, Hägg S. Venous thromboembolism during treatment with antipsychotics: a review of current evidence. CNS Drugs 2018; 32 (01) 47-64
• 82 Kleijer BC, Heerdink ER, Egberts TCG, Jansen PAF, van Marum RJ. Antipsychotic drug use and the risk of venous thromboembolism in elderly patients. J Clin Psychopharmacol 2010; 30 (05) 526-530
• 83 Bernardo M, Rico-Villademoros F, García-Rizo C, Rojo R, Gómez-Huelgas R. Real-world data on the adverse metabolic effects of second-generation antipsychotics and their potential determinants in adult patients: a systematic review of population-based studies. Adv Ther 2021; 38 (05) 2491-2512
• 84 Newcomer JW. Clinical considerations in selecting and using atypical antipsychotics. CNS Spectr 2005; 10 (S10): 12-19
• 85 Holt RIG, Peveler RC. Metabolic syndrome and mental illness. In: Byrne CD, Sarah H, Wild SH. eds. The Metabolic Syndrome. 2nd ed.. Hoboken, NJ: Wiley-Blackwell; 2011: 177-193
• 86 Mackin P, Watkinson HM, Young AH. Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia 2005; 48 (02) 215-221
• 87 Abdel Aziz K, Mohd Ahmed H, Stip E, Aly El-Gabry D. Metabolic syndrome and its relation to antipsychotic polypharmacy in schizophrenia, schizoaffective and bipolar disorders. Int Clin Psychopharmacol 2024; 39 (04) 257-266
• 88 Franz M, Papiol S, Simon MS. et al. Association of clinical parameters and polygenic risk scores for body mass index, schizophrenia, and diabetes with antipsychotic-induced weight gain. J Psychiatr Res 2024; 169: 184-190
• 89 Ishioka M, Yasui-Furukori N, Sugawara N, Furukori H, Kudo S, Nakamura K. Hyperprolactinemia during antipsychotics treatment increases the level of coagulation markers. Neuropsychiatr Dis Treat 2015; 11: 477-484
• 90 Wallaschofski H, Kobsar A, Koksch M. et al. Prolactin receptor signaling during platelet activation. Horm Metab Res 2003; 35 (04) 228-235
• 91 Liperoti R, Pedone C, Lapane KL, Mor V, Bernabei R, Gambassi G. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med 2005; 165 (22) 2677-2682
• 92 Hägg S, Bate A, Stahl M, Spigset O. Associations between venous thromboembolism and antipsychotics. A study of the WHO database of adverse drug reactions. Drug Saf 2008; 31 (08) 685-694
• 93 Axelsson S, Hägg S, Eriksson AC, Lindahl TL, Whiss PA. In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation. Clin Exp Pharmacol Physiol 2007; 34 (08) 775-780
• 94 Carrizo E, Fernández V, Quintero J. et al. Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. Schizophr Res 2008; 103 (1–3): 83-93
• 95 Wilkowska A, Kujawska-Danecka H, Hajduk A. Risk and prophylaxis of venous thromboembolism in hospitalized psychiatric patients. A review. Psychiatr Pol 2018; 52 (03) 421-435
• 96 Barbar S, Noventa F, Rossetto V. et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 2010; 8 (11) 2450-2457
• 97 Ruhe AM, Hebbard A, Hayes G. Assessment of venous thromboembolism risk and initiation of appropriate prophylaxis in psychiatric patients. Ment Health Clin 2018; 8 (02) 68-72
• 98 Hilger H, von Beckerath O, Kröger K. Prophylaxis of venous thromboembolism in physically restrained psychiatric patients. Int J Psychiatry Clin Pract 2016; 20 (03) 187-190